Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Asthenia, elevated liver enzymes, and weight gain each occurred in fewer than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback